a slight trendP = 0.385
Regarding OS data after 2L line, we saw only a slight trend in favour of the Neo-RAS wt patients treated with anti-EGFR (33.6 mo vs 32.4 mo, P = 0.385), statistically limited due to sample size.
Regarding OS data after 2L line, we saw only a slight trend in favour of the Neo-RAS wt patients treated with anti-EGFR (33.6 mo vs 32.4 mo, P = 0.385), statistically limited due to sample size.